艾迪亚生物科技

最新新闻

• 评级变动
  Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  Goldman Sachs Maintains IDEAYA Biosciences(IDYA.US) With Hold Rating, Raises Target Price to $36
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Cadrenal Therapeutics, Inc. (CVKD) and IDEAYA Biosciences (IDYA)
  TipRanks · 2026/6/16
• 评级变动
  RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $48
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  UBS Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/6/9
• 评级变动
  Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $54
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Citizens JMP Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $57
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48
  \u5e02\u573a\u8d44\u8baf · 2026/8/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。